Atrium Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RNA and other ETFs, options, and stocks.

About RNA

Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. 

CEO
Kathleen Gallagher
CEOKathleen Gallagher
Employees
—
Employees—
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
Founded
Employees
—
Employees—

RNA Key Statistics

Market cap
182.55M
Market cap182.55M
Price-Earnings ratio
—
Price-Earnings ratio—
Dividend yield
—
Dividend yield—
Average volume
202.47K
Average volume202.47K
High today
$8.21
High today$8.21
Low today
$7.79
Low today$7.79
Open price
$8.06
Open price$8.06
Volume
192.61K
Volume192.61K
52 Week high
$16.77
52 Week high$16.77
52 Week low
$7.49
52 Week low$7.49

Stock Snapshot

Atrium Therapeutics(RNA) stock is priced at $8.20, giving the company a market capitalization of 182.55M.

On 2026-10-23, Atrium Therapeutics(RNA) stock traded between a low of $7.79 and a high of $8.21. Shares are currently priced at $8.20, which is +5.3% above the low and -0.1% below the high.

Atrium Therapeutics(RNA) shares are trading with a volume of 192.61K, against a daily average of 202.47K.

During the past year, Atrium Therapeutics(RNA) stock moved between $7.49 at its lowest and $16.77 at its peak.

During the past year, Atrium Therapeutics(RNA) stock moved between $7.49 at its lowest and $16.77 at its peak.

RNA News

TipRanks 2d
Atrium Therapeutics initiated with a Buy at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Atrium Therapeutics (RNA) with a Buy rating and $15 price target The company aims to extend tar...

People also own

Based on the portfolios of people who own RNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.